Skip to main content
Contact Us
Sign Up
Subscriber Sign In
English
日本語
navigation
Search
COVID-19
COVID-19 Partnering Event
COVID-19 Update
COVID-19 EventAnalyzer
Evaluate Vantage COVID-19 Report
COVID-19 Stories from Evaluate Vantage
Evaluate’s Business Continuity Plan
What We Do
Commercial Intelligence
Products
EvaluatePharma
EvaluatePharma Vision
Japan Drug Forecasts
European Drug Forecasts
Epi Analyzer
Evaluate Custom Solutions
Evaluate Vantage
News
Analysis
Policy & Pricing
Data Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
How We Can Help You
Pharma and Biotech
Medtech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
English
日本語
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Careers
Current Vacancies
Contact Us
Sign Up for Evaluate Vantage
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Data Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Renovo
March 20, 2014
Circassia joins the exclusive $100m+ IPO club
February 06, 2014
Circassia resists Nasdaq lure and puts its faith in London
October 04, 2011
Pharmasset continues to lead small cap gainers so far in 2011
July 05, 2011
Pharmasset success story leads small caps in first half of 2011
April 04, 2011
Pharmasset the stand out small cap performer in first quarter
April 04, 2011
Pharmasset the stand out small cap performer in first quarter
February 15, 2011
Vantage Point - UK life sciences sector suffering from dire start to year
February 15, 2011
EP Vantage Interview - Proximagen chasing smarter deals
February 11, 2011
Renovo could be fatally wounded by trial failure
March 25, 2010
Capstone attempts to 'put' shareholders first
February 16, 2009
EP Vantage Interview – Algeta targeting deal as phase III trial wins US approval
Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
April 16, 2020
Evaluate Vantage COVID-19 Report
February 20, 2020
Evaluate Vantage Pharma, Biotech & Medtech 2019 in Review
Editor's Picks
April 22, 2020
Covid-19 antibody tests face a very specific problem
April 23, 2020
Covid-19’s clinical damage starts to emerge
April 23, 2020
The crucial data readouts coming soon for small biotechs
April 22, 2020
AACR 2020 preview – no Tigit, but plenty of novel mechanisms
April 03, 2020
The long path to an effective coronavirus vaccine
